Avadel Pharmaceuticals PLC expected to post a loss of 29 cents a share - Earnings Preview

Avadel Pharmaceuticals

27/02/2024 22:18

* Avadel Pharmaceuticals PLC  AVDL.OQ   AVDL.O  is expected
to show a rise in quarterly revenue when it reports  results on
February 29 for the period ending December 31 2023
    * The Dublin-based  company is expected to report revenue of
$18.111 million, according to the mean estimate from 8 analysts,
based on LSEG data.The company's guidance on January 8 2024, for
the period ended December 31, was for revenue of $19.000
million.
    * ​LSEG's mean analyst estimate for Avadel Pharmaceuticals
PLC is
for a loss of 29 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Avadel
Pharmaceuticals PLC is $20.00​, above​ its last closing price
of $12.99. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.38       -0.37      -0.41     Missed  -10.1
 Jun. 30 2023  -0.38       -0.38      -0.83     Missed  -116
 Mar. 31 2023  -0.34       -0.38      -0.48     Missed  -27.4​
 Dec. 31 2022  -0.30       -0.27      -0.46     Missed  -69.7
 ​​Sep.        -0.21       -0.25      -0.33     Missed  -30.3
 30 2022                                                
 Jun. 30 2022  -0.39       -0.41      -1.01     Missed  -146.5
                                                        ​
 Mar. 31 2022  -0.43       -0.43      -0.45     Missed  -4
 Dec. 31 2021  -0.41       -0.41      -0.38     Beat    8.2
 This summary was machine generated February 27 at 22:18 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)